Last reviewed · How we verify

Vancomycin or Fidaxomicin — Competitive Intelligence Brief

Vancomycin or Fidaxomicin (Vancomycin or Fidaxomicin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic (Glycopeptide / Macrocyclic). Area: Infectious Disease.

phase 3 Antibiotic (Glycopeptide / Macrocyclic) Bacterial cell wall (Vancomycin) / Bacterial RNA polymerase (Fidaxomicin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vancomycin or Fidaxomicin (Vancomycin or Fidaxomicin) — Sejtterapia Kozpont Kft.. Vancomycin and Fidaxomicin are antibiotics that inhibit bacterial cell wall synthesis or protein synthesis to treat Clostridioides difficile infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vancomycin or Fidaxomicin TARGET Vancomycin or Fidaxomicin Sejtterapia Kozpont Kft. phase 3 Antibiotic (Glycopeptide / Macrocyclic) Bacterial cell wall (Vancomycin) / Bacterial RNA polymerase (Fidaxomicin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic (Glycopeptide / Macrocyclic) class)

  1. Sejtterapia Kozpont Kft. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vancomycin or Fidaxomicin — Competitive Intelligence Brief. https://druglandscape.com/ci/vancomycin-or-fidaxomicin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: